Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)

N/ANot Yet RecruitingNCT05072015

University Hospital, Strasbourg, France150 enrolled

Overview

Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: * Motor complications evolution at 6 months, 2 and 3 years * MDS UPDRS III score at 6 months, 1, 2 and 3 years * non motor complications evolution at 6 months, 1, 2 and 3 years * cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years * cutaneous and digestive complications at 6 months, 1, 2 and 3 years * neuropathy occurrence at 6 months, 1, 2 and 3 years * medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Parkinson's Disease

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion criteria: * Parkinson disease (UKPDSSB criteria) * Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump * MOCA \>20 * patient \>21 years of age * patient who has signed protocol acceptation Exclusion criteria: * patient who did not give his acceptation for the protocol * patient with another parkinsonian syndrome than Parkinson' s disease * MOCA\<20 * Patient who does not need second line treatment

Locations (1)

Mathieu ANHEIM

Strasbourg, France

Outcomes

Primary Outcomes

MDS UPDRS IV (Movement Disorder Society - Unified Parkin-son Disease Rating Scale) score improvement

Evaluate the evolution of motor fluctuations and dyskinesias at one year in patients. treated with one of the 3 TSLs (bilateral stimulation of the subthalamic nucleus, apomorphine pump and duodopa pump. the higher the score, the more the disease is installed

Time frame: 1 year